Table 3.
Demographic and histopathologic characteristics of cohort B
| All patients (n = 46) |
Seizure patients (n = 23) |
Seizure-free patients (n = 23) |
p value (seizure vs. non-seizure) | ||
|---|---|---|---|---|---|
| Age | Years | 53.91 +/- 17.85 | 50.43 +/- 20.22 | 57.39 +/- 14.75 | 0.222 |
| Sex | Female | 20 (43.5%) | 12 (52.2%) | 8 (34.8%) | 0.234 |
| Diagnosis | Glioblastoma, IDH-wildtype | 24 (52.2%) | 7 (30.4%) | 17 (73.9%) | 0.005 |
| Gliosarcoma, IDH-wildtype | 1 (2.2%) | 1 (4.3%) | 0 (0.0%) | ||
| Astrocytoma, IDH-mutant | 6 (13.0%) | 2 (8.7%) | 4 (17.4%) | ||
| Oligodendroglioma, IDH-mutant & 1p/19q-codeleted | 9 (19.6%) | 8 (34.8%) | 1 (4.3%) | ||
| Formerly diagnosed as anaplastic Astrocytoma/ Oligodendroglioma WHO °III, IDH-wt, NOS | 3 (6.5%) | 2 (8.7%) | 1 (4.3%) | ||
| Ganglioglioma | 1 (2.2%) | 1 (4.3%) | 0 (0.0%) | ||
| Pilocytic astrocytoma | 2 (4.3%) | 2 (8.7%) | 0 (0.0%) | ||
| CNS WHO grade | 4 | 26 (56.5%) | 9 (39.1%) | 17 (73.9%) | 0.051 |
| 3 | 13 (28.3%) | 9 (39.1%) | 4 (17.4%) | ||
| 2 | 4 (8.7%) | 2 (8.7%) | 2 (8.7%) | ||
| 1 | 3 (6.5%) | 3 (13.0%) | 0 (0.0%) | ||
| IDH-1 status | mutated | 15 (32.6%) | 10 (43.5%) | 5 (21.7%) | 0.070 |
| 1p19q status | Codeleted | 11 (23.9%) | 10 (43.5%) | 1 (4.3%) | 0.005 |
| Wildtype or missing | 35 (76.1%) | 13 (56.5%) | 22 (95.7%) | ||
| MGMT status | Methylated | 30 (65.2%) | 16 (69.6%) | 14 (60.9%) | 0.241 |
| Unmethylated or missing | 12 (26.1%) | 4 (17.4%) | 8 (34.8%) | ||
| N/A | 4 (8.7%) | 3 (13.0%) | 1 (4.3%) | ||
| Localization | Frontal | 23 (50.0%) | 14 (60.9%) | 9 (39.1%) | 0.418 |
| Parietal | 10 (21.7%) | 3 (13.0%) | 7 (30.4%) | ||
| Temporal | 10 (21.7%) | 5 (21.7%) | 5 (21.7%) | ||
| occipital | 1 (2.2%) | 0 (0.0%) | 1 (4.3%) | ||
| multifocal | 2 (4.3%) | 1 (4.3%) | 1 (4.3%) |